The Brazilian pharmaceutical company Unión Química will produce a Covid-19 Russian vaccine of which it is expected today to manufacture up to eight million doses per month.

Axar.az reports citing foreign media that company´s authorities confirmed.

The G1 news portal assured that such revalidation was issued to a foreign news agency by the company's International Business Director Rogerio Rosso.

Such a phase is a trial used in humans. Although it is included in the request, ANVISA did not reveal the number of volunteers or the places where the research must be carried out in the country, if it is approved.

The vaccine developed by the Gamaleya Research Institute, is the same immunizer that was applied in Argentina and Belarus, and the first one to be worldwide registered to fight Covid-19 in August.

Russia recently published some data with the final result of the vaccine's effectiveness, with 91%.